Clinical Trial: A randomized, double-blind, placebo-controlled study to evaluate ferric carboxymaltose therapy in patients with cardiac amyloidosis combined with iron deficiency (Reward) (China)

China, Sept. 21 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A randomized, double-blind, placebo-controlled study to evaluate ferric carboxymaltose therapy in patients with cardiac amyloidosis combined with iron deficiency (Reward)'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132906

Registration Time: 2026/09/20

Type: Interventional study

Primary Sponsor: Fuwai Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=344311

Published by HT Digital Content Services with permission from Health Daily Digest....